{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:34Z","timestamp":1791520834279,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.4158\/ep-2020-0277","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:50:06Z","timestamp":1594637406000},"page":"1416-1424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism"],"prefix":"10.1016","volume":"26","author":[{"given":"Yuta","family":"Tezuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina F.","family":"Turcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2020-0277_bb0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"10.4158\/EP-2020-0277_bb0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism: practical approach to diagnosis and management","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"key":"10.4158\/EP-2020-0277_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0035","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.4158\/EP-2020-0277_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP-2020-0277_bb0045","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2020-0277_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J"},{"key":"10.4158\/EP-2020-0277_bb0060","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.4158\/EP-2020-0277_bb0065","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2020-0277_bb0075","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.4158\/EP-2020-0277_bb0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2020-0277_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.4158\/EP-2020-0277_bb0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/a-0604-3249","article-title":"Mineralocorticoid receptor blockers and aldosterone to renin ratio: a randomized controlled trial and observational data","volume":"50","author":"Pilz","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2020-0277_bb0095","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa080","article-title":"Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism-the EMIRA Study","author":"Rossi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0100","series-title":"RDW\/DataDirect: a self-serve tool for data retrieval","author":"Kheterpal","year":"2015"},{"key":"10.4158\/EP-2020-0277_bb0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.13442","article-title":"Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism","volume":"87","author":"Nanba","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2020-0277_bb0110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/HYPERTENSIONAHA.119.12935","article-title":"Primary aldosteronism","volume":"74","author":"Funder","year":"2019","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1530\/EJE-17-0978","article-title":"Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms","volume":"178","author":"Heinrich","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"10.4158\/EP-2020-0277_bb0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1573402113666170228151402","article-title":"Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism","volume":"13","author":"Chrissobolis","year":"2017","journal-title":"Curr Hypertens Rev"},{"key":"10.4158\/EP-2020-0277_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tem.2015.01.007","article-title":"Emerging cardiovascular indications of mineralocorticoid receptor antagonists","volume":"26","author":"Parviz","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/jc.2018-01299","article-title":"Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism","volume":"104","author":"Nanba","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0145","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/jc.2014-2788","article-title":"Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy","volume":"99","author":"Haase","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1976.tb04883.x","article-title":"Canrenone--the principal active metabolite of spironolactone?","volume":"3","author":"Ramsay","year":"1976","journal-title":"Br J Clin Pharmacol."},{"key":"10.4158\/EP-2020-0277_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cpt1976202167","article-title":"Spironolactone and potassium canrenoate in normal man","volume":"20","author":"Ramsay","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.4158\/EP-2020-0277_bb0160","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the miner-alocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0165","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.4158\/EP-2020-0277_bb0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0175","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","article-title":"Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014","volume":"68","author":"Hwang","year":"2016","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cen.12882","article-title":"\u03b2-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension","volume":"84","author":"Browne","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2020-0277_bb0185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"10.4158\/EP-2020-0277_bb0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1210\/jcem-41-1-153","article-title":"Potassimaldosterone-renin interrelationships","volume":"41","author":"Himathongkam","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2020-0277_bb0200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/JOE-16-0452","article-title":"Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signaling","volume":"232","author":"Chong","year":"2017","journal-title":"J Endocrinol"},{"key":"10.4158\/EP-2020-0277_bb0205","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20484447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20484447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:08:56Z","timestamp":1761516536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20484447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1530891X20484447"],"URL":"https:\/\/doi.org\/10.4158\/ep-2020-0277","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2020-0277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}